* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Protein Degradation Targeting Antibodies (PROTABs) are an innovative antibody-based targeted protein degradation (TPD) modality designed to selectively remove membrane receptors, transmembrane proteins, and other cell-surface targets that are difficult to modulate with conventional small molecules. Structurally, PROTABs are multispecific antibodies, typically engineered with one arm that binds the protein of interest (POI) and another arm that engages a cell-surface E3 ubiquitin ligase. This dual engagement brings the target protein into proximity with the ligase, triggering ubiquitination, internalization, trafficking, and eventual degradation via cellular pathways. Unlike PROTACs, which are small-molecule bifunctional degraders connected by a chemical linker to recruit intracellular E3 ligases, PROTABs rely on the antibody scaffold itself to position the POI and E3 ligase, eliminating the need for a chemical linker and enabling the degradation of extracellular or membrane-bound proteins that are inaccessible to small molecules.
BOC Sciences offers end-to-end PROTAB technology development services for pharmaceutical, biotechnology, and research organizations aiming to harness antibody-enabled degradation. Our capabilities include target feasibility assessment, binder selection and optimization, cell-surface E3 ligase strategy, bispecific antibody format design, PROTAB construct engineering, ubiquitination validation, degradation assay development, in vitro and cell-based profiling, in vivo research evaluation, and iterative optimization cycles. By integrating antibody engineering with degradation biology and data-driven decision-making, we help clients transform PROTAB concepts into experimentally validated, research-ready programs.
Services
BOC Sciences' Comprehensive PROTAB Technology Development Services
Target Feasibility and Membrane Protein Degradability Assessment
PROTAB development begins with understanding whether the selected POI is accessible, internalization-competent, and biologically suitable for antibody-induced degradation. We evaluate extracellular epitope availability, receptor abundance, membrane topology, turnover rate, trafficking behavior, disease-relevant expression, and assay feasibility to define a practical development route.
Degradability review for receptors, immune checkpoints, and transmembrane proteins
Analysis of extracellular domain accessibility and epitope suitability
Selection of cellular models for surface expression and degradation readouts
Cell-Surface E3 Ligase Strategy
The choice of E3 ubiquitin ligase is central to PROTAB performance. We help clients evaluate cell-surface E3 ligase candidates such as RNF43, ZNRF3, and other membrane-associated ligases based on expression pattern, target proximity, internalization behavior, ubiquitination potential, and compatibility with the selected POI.
E3 ligase selection based on tissue, cell type, and target-expression context
Evaluation of RNF43-, ZNRF3-, and alternative surface E3-recruiting strategies
Risk assessment for insufficient ligase expression or nonproductive target proximity
Bispecific Antibody and Binder Format Design
PROTAB molecules require a format that can simultaneously engage the POI and the selected E3 ligase while supporting productive cellular trafficking. BOC Sciences supports design of bispecific antibody formats, asymmetric IgG-like constructs, Fab-based architectures, single-chain variable fragment (scFv) modules, and binder orientation strategies to improve degradation efficiency.
POI-binding arm and E3-binding arm configuration design
Valency, geometry, spacer, and orientation optimization
Format comparison for degradation potency, internalization, and cellular response
Target-Binding Arm and Epitope Optimization
The target-binding arm must recognize a surface-exposed epitope that supports E3 proximity without simply blocking receptor function. We assist with binder selection, epitope mapping strategy, affinity tuning, competition assessment, and target engagement analysis to improve the probability of productive PROTAB-mediated degradation.
Antibody, peptide, or engineered binder strategy for membrane POIs
Epitope selection to favor target clustering, internalization, and degradation
Binding, internalization, and cell-surface retention assessment
PROTAB Engineering, Production, and Characterization
We support engineering and preparation of PROTAB candidates for research use, including construct design, sequence optimization, antibody-format assembly, expression strategy, and analytical characterization. Our workflow helps clients compare multiple molecular formats and prioritize candidates with stronger expression behavior, binding profile, and degradation potential.
Design of multispecific antibody constructs for POI-E3 co-engagement
Engineering of IgG-like, Fab-Fv, scFv-fusion, and modular antibody formats
Binding evaluation for both target protein and E3 ligase arms
Candidate ranking based on expression, binding, internalization, and degradation data
Mechanistic Validation and Degradation Profiling
Because PROTAB activity depends on target engagement, E3 recruitment, ubiquitination, internalization, and degradation, mechanism-focused validation is essential. We design assay packages that distinguish true PROTAB-driven target loss from antibody masking, receptor shedding, transcriptional downregulation, or nonspecific cellular stress.
PROTAB projects require more than simply combining two binding arms. Productive degradation depends on target biology, E3 ligase biology, antibody geometry, internalization route, ubiquitination efficiency, and assay interpretation. BOC Sciences provides integrated solutions that connect molecular design with experimental validation, helping clients make reliable decisions at each stage of a PROTAB research program.
Solution for Target and E3 Ligase Pairing
A membrane protein may be highly disease-relevant but still difficult to degrade if it does not internalize efficiently or if a compatible surface E3 ligase is absent in the selected cellular context. We address this by comparing target expression, epitope accessibility, E3 ligase abundance, proximity potential, and trafficking behavior. This allows clients to prioritize target-E3 pairs that are biologically plausible before investing in extensive antibody-format engineering.
Solution for Bispecific Format and Geometry Optimization
Strong binary binding does not always translate into efficient degradation. The spatial arrangement of the POI-binding arm and E3-binding arm can determine whether ubiquitination and internalization occur productively. We compare antibody valency, arm orientation, spacer length, and format architecture to identify designs that promote functional POI-E3 proximity while preserving binding to both cell-surface partners.
Solution for Degradation Assay Design
Antibody-based modalities can complicate target quantification because surface epitope masking may mimic target loss. We design orthogonal assays using total protein measurement, surface protein quantification, internalization analysis, imaging, and pathway controls. By integrating time-course and concentration-response studies, we help distinguish real degradation from altered antibody detection, receptor redistribution, or nonspecific cellular effects.
Solution for Iterative Candidate Optimization
Early PROTAB candidates often show partial degradation or narrow activity windows. We use degradation data, binding profiles, internalization kinetics, ubiquitination results, and cellular pathway readouts to guide the next design cycle. This iterative workflow helps refine E3-binding affinity, target epitope choice, valency, format geometry, and assay conditions until a clearer structure-function relationship emerges.
Choose BOC Sciences to Build More Reliable PROTAB Degradation Programs!
From target feasibility and surface E3 ligase strategy to bispecific antibody engineering, degradation assays, mechanistic validation, and iterative optimization, BOC Sciences provides tailored support for PROTAB technology development. Our multidisciplinary expertise helps clients reduce uncertainty and generate decision-ready data for antibody-enabled degradation research.
Our PROTAB Solutions Support Diverse R&D Organizations
Research Institutes and Academic Laboratories
Academic teams use PROTAB technology to study membrane protein biology, receptor trafficking, E3 ligase function, and antibody-induced degradation mechanisms. We support these exploratory projects with flexible target assessment, antibody-format design, and assay modules that generate reliable mechanistic data.
Biotechnology Companies
Biotechnology companies often need rapid proof-of-concept data to determine whether a disease-relevant surface protein can be removed rather than simply blocked. BOC Sciences helps accelerate this process through target-E3 pairing, prototype PROTAB design, degradation screening, and optimization planning.
Pharmaceutical Discovery Teams
Pharmaceutical researchers can use PROTAB development to explore new degradation approaches for oncology, immunology, and receptor-signaling programs. We provide systematic support for target selection, E3 ligase strategy, antibody engineering, cellular degradation profiling, and mechanism-focused validation.
CROs / Technical Service Platforms
CROs and technical platforms may require specialized antibody-based degradation expertise to complement internal discovery capabilities. We offer modular cooperation models covering target assessment, PROTAB design, assay development, ubiquitination analysis, and data interpretation for collaborative research delivery.
Understand the client's target protein, disease or pathway context, available antibodies or binders, preferred E3 ligase strategy, cell models, and desired degradation readouts.
02
Target Feasibility and E3 Ligase Assessment
Evaluate membrane topology, extracellular epitope accessibility, target turnover, E3 ligase expression, internalization potential, and assay feasibility to define a rational PROTAB strategy.
03
Proposal Design, Scope Definition, and Quotation
Prepare a tailored research plan covering construct design, candidate number, binding assays, degradation assays, mechanistic validation, and data reporting objectives.
04
Project Initiation and Technical Data Transfer
Receive target information, antibody sequences or binder materials, cell model details, reference assays, and background data required for efficient execution.
05
PROTAB Construct Design and Engineering
Design multispecific antibody formats that co-engage the membrane POI and cell-surface E3 ligase while optimizing valency, orientation, spacer design, and binding compatibility.
06
In Vitro and Cell-Based Evaluation
Evaluate target engagement, E3 binding, cell-surface target loss, total protein reduction, internalization, ubiquitination, and degradation kinetics in relevant cellular systems.
07
Mechanistic Validation and Optimization
Confirm whether observed target reduction aligns with PROTAB-mediated ubiquitination and trafficking, then refine construct design based on degradation potency, Dmax, and functional readouts.
08
Research Sample Delivery and Data Reporting
Provide PROTAB research materials, experimental datasets, degradation profiles, assay interpretation, and practical recommendations for the next optimization cycle.
Advantages
Advantages of PROTAB Technology
Expands TPD to Cell-Surface Targets
PROTAB technology addresses membrane proteins and extracellular-facing receptor domains that are not accessible to many intracellular small-molecule degrader approaches, expanding the target space for protein degradation research.
Enables Target Protein Removal
Rather than only blocking receptor activation, PROTABs are designed to reduce the abundance of the target protein, enabling deeper interrogation of target dependency and receptor-driven signaling pathways.
Supports Context-Selective Degradation
By selecting cell-surface E3 ligases with context-dependent expression, PROTAB strategies may support more selective degradation in cell types where the target and E3 ligase coexist productively.
Compatible with Antibody Engineering
PROTAB design can leverage antibody-format engineering, epitope selection, valency control, and multispecific architecture optimization to fine-tune target engagement and degradation behavior.
Applications
Applications Supported by Our PROTAB Technology Platform
Oncology Receptor Degradation
PROTAB development for receptor tyrosine kinases and tumor-associated membrane proteins
Exploration of HER2, IGF1R, EGFR-family, and FZD-family degradation strategies
Evaluation of target removal versus receptor-blocking antibody activity
Support for cancer-relevant cell models and pathway response analysis
Immune Checkpoint and Immunology Research
Antibody-based degradation strategies for PD-L1 and other surface immune modulators
Analysis of surface target loss, receptor recycling, and cellular response
Comparative assessment of antibody blocking versus target degradation
Mechanistic studies of cell-surface E3 ligase recruitment in immune-relevant models
Support for target validation where protein removal is more informative than binding inhibition
Case Study
Client Success Stories: PROTAB Technology Development
Project Background
A biotechnology research team wanted to determine whether a HER2-positive cell model could support antibody-induced degradation rather than simple receptor blockade. The client had two HER2-binding antibody candidates with different extracellular epitopes but lacked a clear strategy for selecting a surface E3 ligase, designing a bispecific format, and distinguishing genuine target loss from antibody masking in detection assays.
Our Support
We first profiled HER2 surface abundance and compared candidate E3 ligase expression across three HER2-positive cell lines. Based on the target-E3 co-expression pattern, we designed 12 PROTAB constructs using two HER2-binding arms, two E3-binding arms, and three bispecific geometries. Early screening showed that one HER2 epitope produced strong cell-surface signal reduction but limited total protein loss, suggesting receptor masking rather than efficient degradation. We then shifted to the second epitope and introduced an asymmetric format that improved E3 proximity. In a 24 h cellular degradation assay, the optimized construct achieved more than 65% total HER2 reduction in the best-performing cell model, with supporting evidence from internalization imaging and ubiquitination analysis.
Client Testimonial
BOC Sciences helped us avoid a misleading surface-binding readout and converted our early PROTAB idea into a structured degradation workflow. Their integrated antibody design and assay interpretation were essential for identifying the more productive HER2 degradation format.
Project Background
A drug discovery group was exploring PD-L1 degradation as an alternative to receptor blockade in immune-related cell models. Their first-generation bispecific antibody showed strong binding to PD-L1 and the selected E3 ligase but only weak and inconsistent protein reduction. The client needed help identifying whether the limitation came from epitope choice, E3 engagement, format geometry, or assay design.
Our Support
We performed a structured troubleshooting workflow combining dual-arm binding analysis, surface PD-L1 quantification, internalization kinetics, and total protein measurement. The results suggested that the E3-binding arm was functional, but the original bispecific geometry favored surface retention rather than internalization. We designed eight follow-up constructs with altered arm orientation and spacer architecture. A mid-spacer single-arm Fv-IgG format generated the most consistent degradation profile, reducing total PD-L1 by approximately 55% after 18 h treatment under optimized assay conditions. Additional ubiquitination and trafficking analysis supported an E3-dependent degradation mechanism and gave the client a clearer template for further format optimization.
Client Testimonial
The BOC Sciences team did more than build bispecific antibodies. They helped us understand why our early PD-L1 PROTAB design underperformed and provided a practical path to improve degradation through format redesign and better assay controls.
Why Us
Why Choose BOC Sciences for Your PROTAB Project?
Integrated PROTAB Development Support
We provide coordinated support across target assessment, E3 ligase strategy, antibody-format design, PROTAB engineering, degradation assays, and optimization.
Expertise in Membrane Protein Degradation
Our team understands the design logic of PROTAB, AbTAC, LYTAC, and related extracellular degradation approaches for receptors and cell-surface proteins.
Flexible Modular Service Models
Clients can request single-service support, such as target feasibility or degradation assay development, or end-to-end PROTAB development from concept to optimized candidate series.
Mechanism-Focused Validation
Our validation workflows help determine whether protein loss results from PROTAB-mediated E3 recruitment, ubiquitination, internalization, and degradation rather than assay interference.
Data-Driven Design Iteration
We connect binding, trafficking, ubiquitination, degradation, and functional readouts to guide rational improvement of antibody format, epitope choice, and E3 ligase recruitment.
Clear Reporting and Decision Support
We provide organized experimental datasets, practical interpretation, and actionable recommendations to support the next design, screening, or validation cycle.
PROTAB, or Proteolysis Targeting Antibody, is an antibody-based targeted protein degradation strategy designed mainly for cell-surface and membrane-associated proteins. Instead of simply blocking a receptor or ligand interaction, a PROTAB molecule is engineered to bring the protein of interest into proximity with a degradation-triggering cell-surface component, such as an E3 ligase-associated receptor system. This proximity can promote internalization, ubiquitination-related processing, and degradation, enabling researchers to reduce target protein abundance rather than only inhibit its activity.
How does PROTAB differ from PROTAC?
PROTAC, or Proteolysis Targeting Chimera, is typically a bifunctional small molecule that recruits an intracellular E3 ubiquitin ligase to degrade cytosolic or nuclear proteins through the proteasome pathway. PROTAB uses antibody or multispecific protein formats and is more focused on membrane proteins or extracellularly accessible targets. This makes PROTAB especially valuable when the disease-relevant protein has a large extracellular domain, limited small-molecule binding pockets, or biological functions that are better addressed by protein removal than by conventional receptor blockade.
Which targets are suitable for PROTAB development?
Suitable PROTAB targets are usually membrane proteins with accessible extracellular epitopes, disease-relevant expression patterns, and biological functions that depend on protein abundance at the cell surface. Examples may include receptor tyrosine kinases, immune checkpoint proteins, tumor-associated antigens, and signaling receptors that are difficult to modulate with small molecules alone. Early target assessment should consider epitope accessibility, internalization behavior, target turnover, expression in relevant cell models, and whether degradation can produce a meaningful pathway or phenotypic response.
What are the key challenges in PROTAB development?
PROTAB development is technically challenging because strong target binding alone does not guarantee efficient degradation. The molecule must form a productive complex between the target protein and the degradation-mediating receptor or ligase system. Antibody format, binding valency, epitope position, linker geometry, molecular orientation, internalization rate, and cell-type-specific receptor expression can all affect degradation outcomes. BOC Sciences supports PROTAB projects through target feasibility analysis, multispecific molecule design, degradation assay development, and mechanism-focused optimization to help clients identify workable design directions.
How is PROTAB degradation activity evaluated?
PROTAB activity is evaluated through a combination of target protein quantification, cell-surface expression analysis, dose-response profiling, time-course studies, internalization assessment, and downstream functional readouts. It is important to distinguish true degradation from antibody masking, temporary receptor internalization, nonspecific cytotoxicity, or assay interference. BOC Sciences can help design integrated evaluation workflows that examine total target abundance, surface target depletion, degradation kinetics, pathway dependence, and functional consequences, allowing clients to prioritize PROTAB candidates with clearer mechanism and stronger optimization potential.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Expands TPD to Cell-Surface Targets
